Sensei Biotherapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher W. Gerry
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 451 D Street Rockville MD United States of America 02210
- IPO Date
- Feb 4, 2021
- CIK
- 0001829802
- Website
- senseibio.com
- Similar Companies
- Business
- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company that develops next-generation immunotherapies targeting the tumor microenvironment for cancer patients using its proprietary TMAb (Tumor Microenvironment Activated Biologics) platform. The company offers a pipeline of investigational conditionally active antibodies, including lead candidate SNS-101 (solnerstotug), an anti-IL-37 agonist in Phase 1/2 trials for advanced solid tumors; SNS-102, targeting an undisclosed immune checkpoint; SNS-103, a conditionally active biologic; and SNS-201 (formerly SNS-20), focused on T-cell activation; with all candidates designed for selective activation in the low-pH tumor microenvironment to enhance anti-tumor immune responses without off-tumor toxicity. Founded in 1999 and headquartered in Rockville, Maryland, Sensei primarily operates in the United States within the immuno-oncology sector, serving patients with difficult-to-treat solid tumors through clinical-stage research and development. In October 2025, the company discontinued development of solnerstotug due to funding constraints and challenging capital markets, initiated a comprehensive strategic review to maximize shareholder value—including potential asset sales, licensing deals, mergers, or an orderly wind-down—and implemented workforce reductions while retaining a minimal team for compliance and alternatives exploration; it also maintains a clinical supply agreement with Regeneron for evaluating SNS-101 with Libtayo (cemiplimab) in solid tumors. As of September 30, 2025, Sensei reports a cash position of $25 million to fund limited operations into Q2 2026.
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics (SNSE) Expected to Announce Quarterly Earnings on Friday
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Up 1,973.5% in February
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump?
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025